Medinol Ltd.

15 articles about Medinol Ltd.

• Medinol Receives FDA Approval for Next Generation EluNIR-PERL™ Drug-Eluting Coronary Stent System

  10/24/2023

  Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL™ drug-eluting stent (DES) for the treatment of coronary artery disease.

• 

  Cordis and Medinol Announce FDA Approval of the Innovative EluNIR Drug-Eluting Stent System

  11/30/2017

  Cordis today announced FDA approval of the EluNIR drug-eluting stent for the treatment of patients with narrowing or blockages to their coronary arteries

• Medinol Ltd. Receives CE Mark for the EluNIR Ridaforolimus-Eluting Coronary Stent System, and announces first commercial implantations

  10/26/2017

  Medinol announced that it obtained CE-mark for EluNIR, its novel Drug Eluting Stent featuring a unique stent design with low metal footprint and a proprietary elastomeric coating, both designed to optimize clinical outcomes.

• Medinol Ltd. Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US

  2/16/2017

• Medinol Ltd. Announces Excellent Clinical Results For EluNIR, A Novel Drug Eluting Stent

  12/21/2016

• Medinol Ltd. Receives Approval From The Japanese PMDA To Begin Clinical Study On Novel DES

  11/8/2016

• Medinol Ltd. Announces Outstanding Results In A Randomized Trial Of A New Drug Eluting Stent

  5/17/2016

• Medinol Ltd. U.S. Commercializes Novel Coronary Stent

  12/1/2015

• Medinol Ltd. Completes Enrollment In Randomized, Multicenter, Pivotal Study Of eDES Coronary Stent System

  9/23/2015

• Ariad Pharmaceuticals, Inc. And Medinol Ltd. Announce Initiation Of Two Registration Trials Of The Nirsupreme&#0153 Ridaforolimus-Eluting Stent For Use In Coronary Artery Disease

  1/14/2014

• Medinol Ltd. Goes After Johnson & Johnson's Cordis Corporation in Stent Patent War

  8/28/2013

• Olympus Medical Systems Corp. in Collaboration with Medinol Ltd.; Announces the Release of the X-Suit NIR, a Biliary Metallic Stent Featuring Exceptional Anatomic Conformability

  3/19/2009

• Hydromer, Inc. and Medinol Ltd. Enter Into a Coating Services and Supply Agreement for Stent Placement Catheters

  9/3/2008

• Medinol Ltd. Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System

  5/12/2008

• Cordis Corporation Signs Definitive Agreement with Medinol Ltd. for Global Distribution of Bare Metal Stents

  5/23/2007